Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070832 | 0.87 | CXCR4 (0.39) | CXCR4OPRM1OPRL1KCNH2CCR4 | |
| SCHEMBL4073706 | 0.84 | CXCR4 (0.51) | CXCR4 | |
| SCHEMBL4521932 | 0.82 | CXCR4 (0.39) | CXCR4 | |
| SCHEMBL2695053 | 0.80 | CXCR4 (0.37) | CXCR4OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL4234443 | 0.79 | HRH3 (0.38) | CXCR4ITGB3ITGA2BHRH3 | |
| SCHEMBL2694751 | 0.78 | CXCR4 (0.36) | CXCR4OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL2692227 | 0.77 | HSD11B1 (0.45) | CXCR4OPRM1OPRL1KCNH2HRH3 | |
| SCHEMBL2694422 | 0.77 | ITGB3 (0.36) | CXCR4OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL2695480 | 0.77 | CXCR4 (0.36) | CXCR4OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL2692946 | 0.77 | CXCR4 (0.45) | CXCR4HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009507867-A | — | — | 2009-02-26 | — | — | JP | claimed |
| EP-1928839-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1,3-DIALKYL-1H-PYRAZOL-4-CARBONYL FLUORIDES | Bayer CropScience AG (DE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007031212-A1 | METHOD FOR THE PRODUCTION OF 5-FLUORO-1,3-DIALKYL-1H-PYRAZOL-4-CARBONYL FLUORIDES | BAYER CROPSCIENCE AG (DE) | 2007-03-22 | — | — | WO | claimed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885OPRM1 1350/4885OPRL1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.